Universal Germline Genetic Testing in Prostate Cancer

Authored by Neal Shore, published on 2026-05-07 23:17:10.0

  1. Patient with prostate cancer
    New or existing diagnosis; any stage, pathology, grade group, age, race/ethnicity, or family-history status.
    • Offer comprehensive germline genetic testing (GGT) to all
      Do not rely on restrictive guideline criteria, family history, or histopathology alone; provide timely and equitable access.
      • Patient accepts testing?
        • No - Continue standard prostate cancer care
          Revisit GGT at future visits, disease progression, or when family implications are discussed.
        • Yes - Pretest education / counseling pathway
          Explain treatment implications, hereditary cancer risk, possible results, privacy/insurance issues, and family cascade testing.
          • Order multigene hereditary cancer panel
            Include genes linked to hereditary cancer and/or prostate cancer management, especially DNA damage repair and Lynch/MMR genes.
            • Result category
              • No actionable PGV found
                Manage prostate cancer by standard clinicopathologic risk. Treat VUS (Variant of Uncertain Significance) as non actionable; monitor for variant reclassification if applicable.
              • Hereditary cancer risk actions
                Refer or connect to genetics expertise; initiate syndrome-specific screening/prevention for secondary cancers and cascade testing for at-risk relatives. A PGV/LPV may indicate an inherited cancer syndrome affecting: the patient biologic relatives This branch exists because germline testing has consequences beyond the prostate tumor itself. Example BRCA2 Associated with elevated risk of: breast cancer pancreatic cancer ovarian cancer prostate cancer Example Lynch syndrome genes (MSH2, MLH1, etc.) Associated with: colorectal cancer endometrial cancer urothelial cancers prostate cancer
              • PGV / LPV identified
                PGV = Pathogenic Germline Variant or LPV = Likely Pathogenic Variant. These are inherited mutations believed to meaningfully increase cancer risk and/or affect tumor biology. Examples include: BRCA2 BRCA1 ATM CHEK2 PALB2 MSH2 MSH6
                • Genetics-informed shared decision-making
                  Use variant, disease state, and patient goals to guide management.
                  • Localized low- or intermediate-risk disease
                    High-risk PGV (eg, BRCA2; possibly BRCA1, ATM, NBN, HOXB13): consider more intensive active surveillance, lower threshold for definitive local therapy, and closer monitoring
                  • Localized intermediate- or high-risk disease
                    Germline DDR carrier status should not automatically exclude intensive neoadjuvant androgen-deprivation strategies or definitive local treatment
                  • Advanced, metastatic, or castration-resistant disease
                    Use germline findings with tumor/somatic testing to select precision options: PARP inhibitor strategies for HRR/DDR alterations, immunotherapy for MMR/Lynch biology where indicated, and clinical trials
tosprivacyImplementation of Universal Germline Genetic Testing Into Standard of Care for Patients With Prostate Cancer: The Time Is Now